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Background: Influenza remains a significant problem in elderly despite widespread vaccination coverage.
This randomized, phase-I study in elderly compared different strategies of improving vaccine immuno-
genicity.
Methods: A total of 370 healthy participants (P65 years) were randomized equally 1:1:1:1:1:1 to six
influenza vaccine treatments (approximately 60–63 participants per treatment arm) at day 1 that con-
sisted of three investigational virosomal vaccine formulations at doses of 7.5, 15, and 45 lg HA anti-
gen/strain administered intradermally (ID) by MicronJet600TM microneedle device (NanoPass
Technologies) or intramuscularly (IM), and three comparator registered seasonal vaccines; Inflexal VTM
(Janssen) and MF59 adjuvanted FluadTM (Novartis) administered IM and IntanzaTM (Sanofi Pasteur) admin-
istered ID via SoluviaTM prefilled microinjection system (BD). Serological evaluations were performed at
days 22 and 90 and safety followed-up for 6 months.
Results: Intradermal delivery of virosomal vaccine using MicronJet600TM resulted in significantly higher
immunogenicity than the equivalent dose of virosomal Inflexal VTM administered intramuscularly across
most of the parameters and strains, as well as in some of the readouts and strains as compared with the
45 lg dose of virosomal vaccine formulation. Of 370 participants, 300 (81.1%) reportedP1 adverse event
(AE); more participants reported solicited local AEs (72.2%) than solicited systemic AEs (12.2%).
Conclusions: Intradermal delivery significantly improved influenza vaccine immunogenicity compared
with intramuscular delivery. Triple dose (45 lg) virosomal vaccine did not demonstrate any benefit on
vaccine’s immunogenicity over 15 lg commercial presentation. All treatments were generally safe and
well-tolerated.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Influenza results in about 3–5 million cases of severe illness and
250,000–500,000 deaths every year, globally [1]. Over 90% of these
deaths and 50% of hospitalizations occur among individuals’
P65 years of age [2,3]. Regardless of the progressive increase in
influenza vaccine coverage, the rates of hospitalization and deaths
due to seasonal influenza in elderly individuals have continued to
increase substantially in the past decades [4–6]. The elderlypatients present a particular immunization challenge for influenza
due to the unfortunate combination of reduced immunity
(immunosenescence) and an increased vulnerability to morbidity
and mortality [7,8].
Various strategies have been developed to improve the
immunogenicity of influenza vaccine in this population, which
includes adjuvantation, increasing antigen dose, and more
recently, delivering the vaccines intradermally [6,9–16]. Modern
adjuvant and carrier systems (e.g., virosomes) can increase the
immunogenicity without compromising vaccine safety and tolera-
bility, especially in populations with immunosenescence [17].
Intradermal (ID) administration of vaccines has demonstrated
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route of administration in older adults [14,18]. Attempts to
increase immunogenicity by increasing the antigen content
demonstrated superior relative efficacy over standard dose
[6,14,19,20].
Vaccination of the elderly presents a number of challenges
including suboptimal immunogenicity and hence decreased vac-
cine efficacy [21]. There is an unmet medical need to evaluate
whether the immune response after vaccination can be further
improved through alternative vaccine delivery such as intradermal
delivery, a higher intramuscular dose administration or through
the use of adjuvants [22]. Moreover, to counteract the known phe-
nomenon of immunosenescence in elderly, commonly used
approach is to use a high IM dose or intradermal administration
of a standard or lower vaccine dose [23]. In addition, the device
used for intradermal administration may have an influence on
the antigen delivery to the intradermal layer of the skin, and con-
sequently the level of the immune response and should be taken
into consideration.
The aim of this exploratory study was to perform immuno-
genicity and safety assessments of different administration routes
and doses of influenza vaccine, across investigational virosomal
vaccine formulations and registered vaccine comparators. We used
the European Committee for Medicinal Products for Human Use
(CHMP/EMA) criteria for re-licensure of influenza vaccine as a basis
of analysis and comparison. This study was not designed to make
statistical comparisons of equivalency or non-inferiority across
different vaccines, rather, sample size was planned to meet the
minimal requirements of influenza vaccine re-licensure (e.g. 50
per treatment arm). Several pairwise comparisons of immune
responses of vaccines delivered ID versus IM, standard versus high
dose formulation, and investigational (e.g. adjuvanted) versus
comparator (same dose, IM) were statistically evaluated.2. Materials and methods
2.1. Study population
Medically stable, healthy participants (P65 years) who were
vaccinated against influenza in season 2011–2012 were enrolled
in the study. Exclusion criteria included previous vaccination with
an influenza vaccine for season 2012–2013, previous history of a
serious adverse events [SAE] or allergic reaction to influenza vac-
cine, acute exacerbation of bronchopulmonary infection or other
acute disease, acute febrile illness (temperature P38 C), and par-
ticipation in another clinical trial.Table 1
Study influenza vaccines, type, route of administration, dose and volume.
Vaccine identification Vaccine type/brand
Investigational
Inflexal-ID-MJ-7.5vir Surface purified antigen, inactivated virosomea
Inflexal-ID-MJ-15vir Surface purified antigen, inactivated, virosomea
Inflexal-IM-NS-45vir Surface purified antigen, inactivated, virosomea
Comparators
Inflexal-IM-NS-15vir Inflexal VTM surface purified antigen, inactivated, virosom
Fluad-IM-NS-15adj FluadTM adjuvanted, surface antigen, inactivated
Intanza-ID-SO-15 IntanzaTM split-viron, inactivated
Notes: study vaccines were identified by a naming convention: name-route of administ
ID = intradermal, IM-intramuscular, MJ, MJ600 = MicronJet600TM microneedle (NanoPass
vir = virosomal, adj = adjuvant, HA = Hemagglutinin.
Inflexal VTM (Crucell Switzerland) is seasonal Virosomal Influenza Vaccine (surface antige
FluadTM (Novartis Vaccines and Diagnostics SRL, Italy) adjuvanted with MF-59TM (oil-in
raminidase) influenza vaccine.
IntanzaTM (Sanofi Pasteur, Lyon, France) is an inactivated, split-virion influenza vaccine.
a The purified antigens from inactivated influenza viruses (mainly HA antigens) are p2.2. Study design
This randomized, open-label, phase I study was conducted in 6
centers in Belgium and Germany between November 2012 and July
2013. Elderly participants received influenza vaccine with strain
composition for season 2012–2013 either via IM or ID administra-
tion at baseline (day 1). Serological evaluations were performed at
days 22 (within ±3 days) and 90 (±5 days), and safety was
followed-up for 6 months (±7 days).
In total, 370 Participants were stratified by gender and study
site and randomized approximately equally 1:1:1:1:1:1 by a
web-based procedure to 1 of 6 vaccinations that consisted of three
investigational virosomal influenza vaccine formulations and three
comparator registered seasonal vaccines. Enrolled number of par-
ticipants in each of the 6 treatment arms ranged from 60 to 63
(Table 1).
The study protocol and amendments were reviewed by an inde-
pendent Ethics Committee or Institutional Review Board, as appro-
priate, for each site. All studies were conducted in compliance with
Declaration of Helsinki consistent with Good Clinical Practices and
applicable regulatory requirements. Written informed consent was
obtained from all participants before enrollment.2.3. Vaccines
All vaccines used in this study contained as active ingredient
the following 3 influenza serotypes recommended for vaccine use
during 2012–2013 season: A/California/7/2009 (H1N1), A/Victo-
ria/361/2011 (H3N2), and B/Wisconsin/1/2010 like viruses.
Modern adjuvant and carrier systems (e.g., virosomes) can
increase immunogenicity [24–26] especially in populations with
reduced responsiveness to active immunization [21]. Virosomes
(vir) were produced by inserting purified antigens from inactivated
influenza viruses propagated in fertilized hens’ eggs into a bilayer
of phospholipid vesicles (approximately 150 nm in diameter) com-
posed of predominantly of phosphatidylcholine in phosphate buf-
fered saline [27].
Investigated virosomal influenza vaccines (surface antigen,
inactivated, virosome) were formulated as virosomes containing
influenza antigens from strains for 2012–2013. The formulations
were presented as suspension for injection in a prefilled syringe
(type I glass) fitted with a needle size of 25G and 5/800
(0.5 mm  16 mm) for intramuscular (IM) injection and with
MicronJet600TM microneedle (MJ) device for intradermal (ID) injec-
tion, (a disposable 3-prong 0.6 mm hollowmicroneedle device that
attaches to any standard luer lock or luer tip syringe [NanoPassRoute of administration Dose (lgHA/strain) Volume (mL)
ID (MJ600) 7.5 lg 0.085
ID (MJ600) 15 lg 0.17
IM 45 lg 0.5
e IM 15 lg 0.5
IM 15 lg 0.5
ID 15 lg 0.1
ration-delivery device-dose-adjuvant.
Technologies), NS = needle-syringe, SO = SoluviaTM minineedle (Becton Dickinson),
n, inactivated).
-water emulsion of squalene oil) is a seasonal adjuvanted, subunit (HA and neu-
resented on a phospholipid bilayer vesicle called a virosome.
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formulations at doses of 7.5, 15 lg HA antigen/strain were admin-
istered as 0.085 mL and 0.17 mL respectively delivered with the
MJ600 device into the dermis. The 45 lg HA antigen/strain formu-
lation was delivered as standard 0.5 mL IM injection in the deltoid
muscle.
Comparator registered influenza vaccines were as follows:
Inflexal VTM (Crucell, Switzerland) is an inactivated, subunit (surface
antigen) virosomal seasonal vaccine containing the standard
dosage of 15 lg HA/strain in each 0.5 ml dose for IM injection;
FluadTM with MF-59TM adjuvant, an oil-in-water emulsion of squa-
lene oil (Novartis Vaccines and Diagnostics SRL, Italy) is a seasonal,
adjuvanted, subunit (HA and neuraminidase) influenza vaccine
containing 15 lg HA/strain per 0.5 mL dose administered IM; and
IntanzaTM (Sanofi Pasteur, Lyon, France) is a seasonal, inactivated,
split-virion influenza vaccine containing 15 lg HA/strain per
0.1-ml dose and was administered in the deltoid region using a
prefilled intradermal microneedle injection system (SoluviaTM
[SO], Becton Dickinson; Franklin Lakes, NJ, USA).
The treatment arms were abbreviated using a naming conven-
tion that provided vaccine trade name - route of administration
(ID, IM) - delivery device (MJ, NS [needle-syringe] - antigen content
- adjuvant, or virosome (vir). The three investigated virosomal
influenza vaccines were abbreviated as Inflexal-ID-MJ-7.5vir,
Inflexal-ID-MJ-15vir, and Inflexal-IM-NS-45vir respectively, and
the three comparator vaccines were abbreviated using the same
naming convention as Inflexal-IM-NS-15vir, Fluad-IM-NS-15adj,
and Intanza-ID-SO-15.2.4. Clinical evaluations
2.4.1. Sample collection
Blood samples (10 mL) were collected at baseline (day 1, pre-
dose) and on days 22 and 90 to assess the participants’ immune
response against homologous virus strains. Samples were
aliquoted into small tubes and stored at 615 C until further
analyses.2.4.2. Safety assessments
Safety was evaluated based on solicited local, solicited systemic
and unsolicited adverse events (AE). Tolerability and acceptance of
study vaccine was also assessed. Solicited AEs were collected
through a ‘subject diary card’ for 8 days after vaccination; unso-
licited AEs (including SAEs) were captured by interviews on day
1 and during the subsequent visits on day 22, 90, and 180 or
reported voluntarily. Solicited local AEs were pain at the injection
site, erythema, induration, swelling, and ecchymosis; solicited sys-
temic AEs included fever, malaise and shivering. This was an open-
label study, and because of the use of different administration
routes and doses, blinding was not possible. Hence as per protocol,
site investigators and their clinical collaborators who administered
the study vaccines were not blinded to vaccine treatment arms and
when reporting, or assessing adverse events and their relatedness
to vaccination.2.4.3. Immunogenicity assessments
The following immunogenicity parameters were assessed via
Hemagglutination inhibition assay (HAI) as stipulated according
to European Medicines Agency (EMA) guidelines [28]: Seroprotec-
tion rate (HAI antibody titerP1:40 to be reached in >60% of partic-
ipants); Seroconversion rate (P4-fold increase in HAI antibody
titer and a titer of P1:40 to be reached in >30% of participants);
Geometric mean titer (GMT) fold increase from baseline (>2.0-
fold increase in GMT of HAI antibodies in participants) [28].3. Statistical methods
3.1. Sample size determination
No formal sample size calculation was performed based on
immunogenicity. Different parameters of interest explored were
based on EMA requirements [28]. A limitation of this exploratory
study was that it was not powered to compare the immunogenicity
between the 6 vaccination treatment arms. For the HAI assay,
exploratory pairwise treatment arm comparisons were made with
no multiplicity adjustments for multiple analyses. The number of
pairwise comparisons made was limited to 10 out of the 15 possi-
ble pairwise comparisons.
The sample size of 60 participants for each investigational treat-
ment arm was adequate to detect a SAE rate of approximately 1 in
20. i.e.: if no SAEs were observed among 60 participants, the exact
95% upper confidence limit on SAE rate would be 4.9%.3.2. Statistical analyses
Immunogenicity was evaluated according to the criteria
described in EMA guideline [28]. Seroprotection rates, seroconver-
sion rates, GMT, and fold-increase in GMT from baseline were
calculated. Study was not powered to compare immunogenicity
between all 6 vaccination treatment arms. For HAI assay, explora-
tory pairwise treatment arm comparisons were made, at each time
point, with and without adjustment for preexisting immunity.
Without adjustment, pairwise comparisons between vaccination
treatment arms were made using logistic regression model on indi-
vidual outcome for seroprotection (yes/no) and seroconversion
(yes/no) with vaccination treatment arm as a factor and analysis
of variance model on log-transformed titers for GMTs, and on
log-transformed titer increases for GMT fold increases with vacci-
nation treatment arm as a factor. With adjustment, pairwise com-
parisons were made using a logistic regression model on individual
outcome for seroprotection (yes/no) and seroconversion (yes/no)
with vaccination treatment arm as a factor and baseline log-
transformed HAI antibody titer as a covariate, and using an analy-
sis of variance model on log-transformed titers for GMTs and on
log-transformed titer increases for GMT fold increases with vacci-
nation treatment arm as a factor and baseline log-transformed HAI
antibody titer as a covariate. For all these pairwise treatment arm
comparisons of interest (Supplementary Table 1), 2-sided p-value
<0.05 was considered as statistically significant. As this was an
exploratory study, no adjustment for multiplicity was applied;
number of comparisons made however was minimized. Analyses
were interpreted descriptively. Due to high prevaccination titers
(high seroprotection rates), the adjusted GMT analysis was con-
ducted to crystalize differences between immune responses.
Solicited local and systemic AEs up to day 4 and 8 after vaccina-
tion and unsolicited AEs were summarized descriptively.3.3. Analysis set
Intention-to-treat (ITT) population included all participants
who received a study vaccine and for whom pre and postvaccina-
tion HAI antibody titers were available (day 1 and 22). Safety pop-
ulation included all participants who received a study vaccine and
for whom safety data were available, irrespective of the occurrence
of protocol deviations or violations. Overall, 9 participants
were excluded from the ITT population as their blood samples
were not taken within the time window defined by the protocol.
These included, one participant each from Intanza-ID-SO-15 and
Inflexal-ID-MJ-7.5vir treatment arms, 2 participants each from
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and 3 participants from Fluad-IM-NS-15adj treatment arm.4. Results
Of the 370 participants randomized and vaccinated, 367 (99%)
completed the study. The number of participants that completed
each of the study arms included n = 60 (63 were randomized), in
Fluad-IM-NS-15adj, n = 60 in Intanza-ID-SO-15, n = 61 in Inflexal-
ID-MJ-7.5vir, and Inflexal-ID-MJ-15vir, n = 62 in Inflexal-ID-MJ-Table 2
Summary of study vaccine solicited (up to day 4) adverse events (safety analysis set).
Intramuscular injections (IM)
Inflexal-IM-NS-
15vir (N = 63)
Inflexal-IM-NS-
45vir (N = 62)
Fluad-IM-N
15adj (N =
Solicited local adverse events
Solicited local AEs 29 (46.0%) 35 (56.5%) 36 (57.1%)
Mild 13 (20.6%) 22 (35.5%) 16 (25.4%)
Moderate 11 (17.5%) 8 (12.9%) 16 (25.4%)
Severe 5 (7.9%) 5 (8.1%) 4 (6.3%)
Erythema 19 (30.2%) 20 (32.3%) 15 (23.8%)
Mild 7 (11.1%) 10 (16.1%) 7 (11.1%)
Moderate 8 (12.7%) 6 (9.7%) 4 (6.3%)
Severe 4 (6.3%) 4 (6.5%) 4 (6.3%)
Ecchymosis 4 (6.3%) 3 (4.8%) 1 (1.6%)
Mild 2 (3.2%) 2 (3.2%) 1 (1.6%)
Moderate 2 (3.2%) 0 0
Severe 0 1 (1.6%) 0
Induration 12 (19.0%) 9 (14.5%) 11 (17.5%)
Mild 2 (3.2%) 2 (3.2%) 5 (7.9%)
Moderate 8 (12.7%) 6 (9.7%) 5 (7.9%)
Severe 2 (3.2%) 1 (1.6%) 1 (1.6%)
Pain 21 (33.3%) 28 (45.2%) 28 (44.4%)
Mild 21 (33.3%) 24 (38.7%) 16 (25.4%)
Moderate 0 4 (6.5%) 12 (19.0%)
Unknown 0 0 0
Solicited systemic adverse events
Solicited systemic AE (P1) 8 (12.7%) 5 (8.1%) 7 (11.1%)
Solicited systemic AE (P1)
excluding fevera
8 (12.7%) 4 (6.5%) 5 (7.9%)
Mild 7 (11.1%) 4 (6.5%) 3 (4.8%)
Moderate 1 (1.6%) 0 1 (1.6%)
Severe 0 0 1 (1.6%)
Unknown 0 0 0
Shivering 4 (6.3%) 1 (1.6%) 3 (4.8%)
Mild 3 (4.8%) 1 (1.6%) 3 (4.8%)
Moderate 1 (1.6%) 0 0
Severe 0 0 0
Malaise 7 (11.1%) 3 (4.8%) 3 (4.8%)
Mild 6 (9.5%) 3 (4.8%) 1 (1.6%)
Moderate 1 (1.6%) 0 1 (1.6%)
Severe 0 0 1 (1.6%)
Unknown 0 0 0
Fever (body temp. P38 Cb) 0 1 (1.6) 2 (3.2%)
AE: Adverse event.
See Table 1 footnotes for description of abbreviations used and vaccines studied.
a Note that the severity of the solicited systemic AE fever was not graded.
b Or body temperature reported as unknown (not measured or recorded).45vir, and n = 63 in Inflexal-IM-NS-15vir arm. Demographics and
baseline characteristics were well-balanced between the vaccina-
tion treatment arms. The study included 54% males and 46%
females (Supplementary Table 2).
4.1. Safety
Total of 72.2% participants reported solicited local AEs, which
were related to study vaccine administration. Unsolicited AEs
were reported in 36.8% of participants. Eighteen participants
(4.9%) had at least 1 SAE. Percentage of participants with at leastIntradermal injections (ID)
S-
63)
Intanza-ID-SO-
15 (N = 60)
Inflexal-ID-MJ-
15vir (N = 61)
Inflexal-ID-MJ-
7.5vir (N = 61)
Total
(N = 370)
54 (90.0%) 57 (93.4%) 56 (91.8%) 267
(72.2%)
7 (11.7%) 13 (21.3%) 11 (18.0%) 82
(22.2%)
24 (40.0%) 23 (37.7%) 30 (49.2%) 112
(30.3%)
23 (38.3%) 21 (34.4%) 15 (24.6%) 73
(19.7%)
52 (86.7%) 56 (91.8%) 54 (88.5%) 216
(58.4%)
6 (10.0%) 13 (21.3%) 10 (16.4%) 53
(14.3%)
24 (40.0%) 22 (36.1%) 29 (47.5%) 93
(25.1%)
22 (36.7%) 21 (34.4%) 15 (24.6%) 70
(18.9%)
0 1 (1.6%) 0 9 (2.4%)
0 1 (1.6%) 0 6 (1.6%)
0 0 0 2 (0.5%)
0 0 0 1 (0.3%)
31 (51.7%) 34 (55.7%) 34 (55.7%) 131
(35.4%)
16 (26.7%) 21 (34.4%) 26 (42.6%) 72
(19.5%)
11 (18.3%) 12 (19.7%) 8 (13.1%) 50
(13.5%)
4 (6.7%) 1 (1.6%) 0 9 (2.4%)
22 (36.7%) 11 (18.0%) 15 (24.6%) 125
(33.8%)
19 (31.7%) 10 (16.4%) 11 (18.0%) 101
(27.3%)
3 (5.0%) 1 (1.6%) 3 (4.9%) 23 (6.2%)
0 0 1 (1.6%) 1 (0.3%)
8 (13.3%) 4 (6.6%) 5 (8.2%) 37
(10.0%)
8 (13.3%) 4 (6.6%) 3 (4.9%) 32 (8.6%)
6 (10.0%) 2 (3.3%) 2 (3.3%) 24 (6.5%)
2 (3.3%) 1 (1.6%) 0 5 (1.4%)
0 0 1 (1.6%) 2 (0.5%)
0 1 (1.6%) 0 1 (0.3%)
2 (3.3%) 2 (3.3%) 2 (3.3%) 14 (3.8%)
2 (3.3%) 2 (3.3%) 1 (1.6%) 12 (3.2%)
0 0 0 1 (0.3%)
0 0 1 (1.6%) 1 (0.3%)
7 (11.7%) 3 (4.9%) 2 (3.3%) 25 (6.8%)
5 (8.3%) 1 (1.6%) 1 (1.6%) 17 (4.6%)
2 (3.3%) 1 (1.6%) 0 5 (1.4%)
0 0 1 (1.6%) 2 (0.5%)
0 1 (1.6%) 0 1 (0.3%)
1 (1.7) 0 3 (4.9%) 7 (1.9%)
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was 8.9% for solicited systemic AEs and 15.7% for unsolicited
AEs.
Incidence of solicited local AEs up to day 4 was higher in ID
(Intanza-ID-SO-15, Inflexa-ID-lMJ-7.5vir and Inflexal-ID-MJ-
15vir; 90.0–93.4%) compared with IM treatment arms
(Inflexal-IM-NS-15vir, Fluad-IM-NS-15adj, Inflexal-IM-NS-45vir;
46.0–57.1%) due to higher incidence of erythema and induration
in participants vaccinated intradermally vs. intramuscularly
(erythema: 86.7–91.8% vs 23.8–32.3%, induration: 51.7–55.7%
vs. 14.5–19.0%) (Table 2; Supplementary Table 3). Incidence of
solicited systemic AEs up to day 4 was slightly lower in
Inflexal-ID-MJ-7.5vir, Inflexal-ID-MJ-15vir and Inflexal-IM-NS-
45vir (6.6–8.2%) compared with other treatment arms (11.1–
13.3%). Most common solicited systemic AE was malaise in 25
(6.8%) of 370 vaccinated participants. Incidence of malaise was
higher in participants in Inflexal-IM-NS-15vir treatment arm
(11.1%) and Intanza-ID-SO-15-treatment arm (11.7%) than in
the other treatment arms (3.3–4.9%). Incidences of solicited
local and systemic AEs up to day 8 were very similar to those
up to day 4.
A total of 136 participants (36.8%) had at least 1 unsolicited AE.
Percentage of participants with at least 1 unsolicited AE was high-
est in Inflexal-ID-MJ-7.5vir (44.3%) and Inflexal-IM-NS-45vir treat-
ment arm (38.7%) and with least reported in Fluad-IM-NS-15adj
(31.7%) and Inflexal-ID-MJ-15vir treatment arm (32.8%). Most
common unsolicited AEs were nasopharyngitis (8.9%), injection
site pruritus (5.4%), and headache (4.6%).
At least 1 SAE was reported for 5 participants in Inflexal-ID-MJ-
7.5vir, 5 participants in Inflexal-ID-MJ-15vir, 4 participants in
Fluad-IM-NS-15adj, 2 participants in Inflexal-IM-NS-45vir, and 1
participant each in Inflexal-IM-NS-15vir and Intanza-ID-SO-15
treatment arm (Supplementary Table 4). All non-fatal SAEs were
resolved by the end of study, except for 1 case of severe polymyal-
gia rheumatica (Inflexal-ID-MJ-15vir; 67 years old woman; onset:
day 10). All other SAEs were considered not related to the study
vaccination. There were 3 deaths (Fluad-IM-NS-15adj) reported
during the follow-up phase because of reasons considered not
related to the vaccine (due to postoperative complications follow-
ing oesophagectomy for oesophageal adenocarcinoma (66 years,
male; day 91); due to spinal epidural abscess (76 years, male;Table 3
Summary of main immunogenicity results for study vaccines (with adjustment for preexi
Intramuscular injections (IM)
Inflexal-IM-NS-
15vir (N = 63)
Inflexal-IM-NS-
45vir (N = 62)
Flu
15a
Days 22 90 22 90 22
Seroconversiona (%)
A/California/7/2009 42.9 28.6 45.2 25.8 50.
A/Victoria/361/2011 38.1 28.6 53.2 43.5 69.
B/Hubei-Wujiagang/158/2009 19.0 14.3 25.8 16.1 31.
Seroprotectionb (%)
A/California/7/2009 88.9 82.5 95.2 93.5 93.
A/Victoria/361/2011 93.7 92.1 98.4 96.8 100
B/Hubei-Wujiagang/158/2009 27.0 20.6 32.3 22.6 38.
GMT fold increase from baselinec
A/California/7/2009 3.59 2.53 3.99 2.45 5.3
A/Victoria/361/2011 4.14 3.36 4.79 3.70 6.2
B/Hubei-Wujiagang/158/2009 2.25 1.74 2.79 2.10 3.5
Note: Percentages are based on number of available observations; p-value is based on a l
when adjusting for baseline log transformed HAI antibody titer.
See Table 1 footnotes for description of abbreviations used and vaccines studied.
a Seroconversion is defined as P4-fold increase in HAI antibody titer compared to ba
b Seroprotection is defined as a HAI antibody titer of P1:40.
c GMT (increase) ratio and p-value are based on an analysis of variance model on lo
(baseline HAI antibody titer value) as a covariate; results are back-transformed to originday 133); due to natural causes (79 years, male; day 162). All other
participants completed the study.
4.2. Immunogenicity
Immunogenicity parameters assessed based on results from the
HAI assay against homologous strains are presented based on the
analysis with adjustment for preexisting immunity. The baseline
GMT titers and seroprotection rates were relatively high for strains
A/California/7/2009 and A/Victoria/361/2011.
4.2.1. Seroconversion rate
Immunogenicity results for day 22 and day 90 were not statis-
tically compared across the six vaccine treatment arms. Serocon-
version rate was above the threshold (>30%) specified by the
EMA [28] in all study arms except for Inflexal-IM-NS-15vir and
Inflexal-IM-NS-45vir in B/Hubei-Wujiagang/158/2009 strain
(Table 3). On day 22, seroconversion rate trended higher in
Inflexal-ID-MJ-15vir (65.6%) for strain A/California/7/2009
whereas it was numerically higher in Fluad-IM-NS-15adj (69.8%)
and Intanza-ID-SO-15 (46.7%) for strain A/Victoria/361/2011 and
B/Hubei-Wujiagang/158/2009, respectively compared with other
vaccines (Table 3). On day 90, seroconversion rates were numeri-
cally lower in all 6 vaccines compared to day 22.
Ten treatment arm-wise comparisons of percentage serocon-
version rates per strain (on day 22 and day 90) between selected
investigational and comparator vaccine arms (adjusted for pre-
existing immunity) were made and the pairwise difference in sero-
conversion rates with 2-sided 95% CI and p-values were deter-
mined. The data for these pairwise comparisons for day 22 is
shown in Fig. 1.
Significantly higher seroconversion rates (p < 0.05) were
observed for the following pairwise comparisons: Inflexal-ID-MJ-
15vir vs. Inflexal-IM-NS-15vir (day 22 and 90), Inflexal-ID-MJ-
15vir vs. Fluad-IM-NS-15adj (day 22), and Inflexal-ID-MJ-15vir
vs. Inflexal-IM-NS-45vir (day 22) for strain A/California/7/2009;
Inflexal-ID-MJ-15vir vs. Inflexal-IM-NS-15vir (day 22) and
Inflexal-ID-MJ-7.5vir vs. Inflexal-IM-NS-15vir (day 90) for strain
A/Victoria/361/2011; and Inflexal-ID-MJ-7.5vir vs. Inflexal-IM-
NS-15vir (day 22) and Inflexal-ID-MJ-15vir vs. Inflexal-IM-NS-
15vir (day 22) for B/Hubei-Wujiagang/158/2009 strain. The daysting immunity, ITT population).
Intradermal injections (ID)
ad-IM-NS-
dj (N = 63)
Intanza-ID-SO-
15 (N = 60)
Inflexal-ID-MJ-
15vir (N = 61)
Inflexal-ID-MJ-
7.5vir (N = 61)
90 22 90 22 90 22 90
8 39.7 53.3 43.3 65.6 44.3 49.2 37.7
8 60.3 58.3 48.3 60.7 44.3 49.2 47.5
7 27.0 46.7 25.0 34.4 16.4 36.1 26.2
7 92.1 93.3 88.3 98.4 90.2 98.4 95.1
96.8 98.3 96.7 98.4 91.8 98.4 96.7
1 31.7 58.3 36.7 39.3 23.0 44.3 39.3
7 3.35 5.02 3.04 5.60 3.16 4.70 3.10
4 4.42 5.06 3.71 6.31 4.40 6.51 4.88
8 2.49 4.61 2.77 3.46 2.26 2.89 2.21
ogistic regression model with vaccination treatment arm as an explanatory variable
seline and a titer of P1:40.
g transformed GMTs (GMRs) with vaccination treatment arm as a factor and log
al scale.
Y. Levin et al. / Vaccine 34 (2016) 5262–5272 526790 data is not presented in the figure as the results were similar to
that of day 22. Since Fluad-IM-NS-15adj and Intanza-ID-SO-15
treatment arm were only used as comparators for the investiga-
tional treatment arms, limited comparisons were made with them
as follows: Fluad-IM-NS-15adj was only compared with Inflexal-
ID-MJ-15vir and Inflexal-IM-NS-45vir and, Intanza-ID-SO-15 with
Inflexal-ID-MJ-7.5vir and Inflexal-ID-MJ-15vir treatment arm;
however the results were not statistically significant, except for
strain A/California/7/2009.
4.2.2. Seroprotection rate
In all 6 treatment arms of all strains, seroprotection rate was
above the threshold (>60%; on days 22 and 90) specified by the
EMA [28], except for strain B/Hubei-Wujiagang/158/2009 (Table 3).Fig. 1. Immunogenicity - seroconversion adjusted forOn day 22, the seroprotection rates trended higher in Inflexal-ID-
MJ-7.5vir and Inflexal-ID-MJ-15vir (98.4%) for strain A/Califor-
nia/7/2009 and in Fluad-IM-NS-15vir (100%) for strain A/Victo-
ria/361/2011. For strain B/Hubei-Wujiagang/158/2009, rates were
numerically higher in Intanza-ID-SO-15 (58.3%) compared with
other treatment arms.
Pairwise comparisons of investigational vs. comparator vacci-
nes for seroprotection rates (day 22, per strain) with percentage
differences, 95% CI and p-values are shown in Fig. 2 (data for day
90 not presented). No comparisons were statistically significant,
neither for day 22 nor for day 90 for strains A/California/7/2009
and A/Victoria/361/2011 after adjustment for preexisting immu-
nity. However for strain B/Hubei-Wujiagang/158/2009, signifi-
cantly higher seroprotection rates (p < 0.05) were observed inpre-existing immunity - day 22 - ITT population.
5268 Y. Levin et al. / Vaccine 34 (2016) 5262–5272Inflexal-ID-MJ-7.5vir vs. Inflexal-IM-NS-15vir on day 22 and 90
and in Inflexal-ID-MJ-15vir vs. Inflexal-IM-NS-15vir on day 22
(Table 3; Fig. 2).
4.2.3. GMT fold increase
In all vaccine treatment arms for all strains, GMT fold increase
was above the threshold (>2.0) specified by the EMA, except in
Inflexal-IM-NS-15vir for strain B/Hubei-Wujiagang/158/2009 on
day 90 (Table 3). GMT values ranged between 35.66 and 53.28 at
baseline, between 152.25 and 237.62 on day 22, and between
103.85 and 141.87 on day 90 for strain A/California/7/2009;
between 42.41 and 72.20 at baseline, between 236.77 and 372.89
on day 22, and between 192.39 and 279.62 on day 90 for strain
A/Victoria/361/2011; and between 6.91 and 8.88 at baseline,Fig. 2. Immunogenicity - seroprotection adjusted forbetween 17.47 and 35.78 on day 22, and between 13.50 and
21.52 on day 90 for strain B/Hubei-Wujiagang/158/2009.
Pairwise comparisons of investigational vs. comparator vacci-
nes for GMT fold increases from baseline (day 22, per strain) with
GMT fold increase ratios, 95% CI and p-values are shown in Fig. 3
(data for day 90 not presented). Significantly higher GMT fold
increases from baseline (p < 0.05) were observed in Inflexal-ID-
MJ-15vir vs. Inflexal-IM-NS-15vir on days 22 and Fluad-IM-NS-
15adj vs. Inflexal-IM-NS-45vir on day 90 (strain A/Califor-
nia/7/2009), Inflexal-ID-MJ-7.5vir and Inflexal-ID-MJ-15vir vs.
Inflexal-IM-NS-15vir on day 22 (strain A/Victoria/361/2011) and
Inflexal-ID-MJ-15vir vs. Inflexal-IM-NS-15vir and Intanza-ID-SO-
15 vs. Inflexal-ID-MJ-7.5vir on day 22 (strain B/Hubei-
Wujiagang/158/2009) (Table 3; Fig. 3).pre-existing immunity - day 22 - ITT population.
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In this study we report one of the first clinical trials comparing
two major approaches to improve influenza vaccine effectiveness:
intradermal delivery, high-dose content with other approaches
such as alternative ID devices and adjuvantation. The focus of this
study was not to evaluate either accomplished strategies (Intanza-
ID-SO-15 and Fluad-IM-NS-15adj) vs. commercial Inflexal-IM-NS-
15vir presentation. Both approaches were evaluated separately or
conjointly in previous clinical studies and have reported divergent
effects [29–39]. Immunogenicity evaluations of study vaccines
were exploratory in nature and the study was limited and not
statistically powered to make comparisons of equivalency orFig. 3. Immunogenicity - geometric mean ratio (GMT fold increase)non-inferiority across different vaccine modalities with no formal
hypothesis testing. As this was an exploratory study, no adjust-
ment for multiplicity was applied for pairwise comparisons of
interest however; total number of comparisons was minimized.
The immune response to influenza vaccination can be influ-
enced by previous influenza vaccinations due to concern with the
ability of influenza vaccine to induce seroconversion. EMA guid-
ance requirements for yearly clinical trials exclude recruiting
healthy volunteers receiving influenza vaccine within the previous
6 months. In this study, vaccination against influenza in the 2011–
2012 season was an inclusion criterion whereas previous vaccina-
tion with an influenza vaccine for season 2012–2013 were
excluded from enrollment. Influenza-vaccine ‘‘naives” were notadjusted for pre-existing immunity - day 22 - ITT population.
5270 Y. Levin et al. / Vaccine 34 (2016) 5262–5272included in the study population in order to obtain a more
homogenous population and all immunogenicity results at each
time point was adjusted for the baseline antibody level to account
for preexisting immunity.
We used the CHMP/EMA guideline for re-licensure of influenza
vaccine as a basis of exploratory immunogenicity analyses and
comparison of investigational and licensed vaccines. To our knowl-
edge at the time of this study no other guidelines for such assess-
ment were available and the EMA regulatory guidelines are widely
used in industry for yearly clinical trials and yearly licensing of
influenza vaccines in Europe [40].
In our study, intradermal approach with MicronJet600TM device
used in Inflexal-ID-MJ-7.5vir and Inflexal-ID-MJ-15vir suggested
overall favourable immunogenicity as compared with Inflexal-
IM-NS-15vir (standard dose) and Inflexal-IM-NS-45vir (high dose)
in elderly population for 2 of the 3 strains. High dose (45 lg) inves-
tigational virosomal formulation did not demonstrate any benefit
on vaccine’s immunogenicity over 15 lg commercial IM presenta-
tion. In addition, Inflexal-IM-NS-45vir had numerically lower
seroconversion rate for strain A/California compared with
Inflexal-ID-MJ-15vir, lower seroprotection for strain B vs.
Inflexal-ID-MJ-7.5vir, and lower in GMT fold increase vs. Inflexal-
ID-MJ-15vir and Fluad-IM-NS-15adj. Fluad-IM-NS-15adj and
Intanza-ID-SO-15 appeared to have good immunogenicity across
all strains, although direct comparisons with Inflexal-IM-NS-
15vir were not conducted in this study. The immunogenicity of
B/Hubei-Wujiagang/158/2009 was consistently lower than that
for the A-strains, both at baseline and days 22 and 90. The HAI
assay, the standard assay for immunogenicity of influenza vacci-
nes, is well known to have a relatively low specificity to influenza
B-viruses in human sera [41].
Previous clinical studies have focused mostly on specific
approaches vs. their standard dose (15 lg) unadjuvanted presenta-
tions, and have generally been able to demonstrate superior
immune responses. FluzoneTM High-Dose vaccine, for example,
demonstrated both improved immunogenicity[6,14,16] as well as
a 24% additional vaccine efficacy in a phase IV study [19]. In
another study [42], FluadTM demonstrated improved immunogenic-
ity when compared with its unadjuvanted pair FluvirinTM; by day
21, HAI and microneutralization (MN) antibody titers of about
1:40 were reported in 77–96% (HAI) and 92–100% (MN) of partic-
ipants receiving MF59-adjuvanted vaccine, compared with 63–72%
(HAI) and 67–76% (MN) of those who received non-adjuvanted
vaccine.
Both the ID administered 7.5 lg and 15 lg dose and the 45 lg
IM dose of virosomal influenza vaccine were generally safe and
well tolerated. Incidence of solicited local AEs up to day 4 was
higher in ID treatment arms (90.0–93.4%) compared with IM
(46.0–57.1%) because of a higher incidence of erythema and
induration in participants vaccinated intradermally vs intramuscu-
larly (erythema: 86.7–91.8% vs 23.8–32.3%, induration: 51.7–55.7%
vs 14.5–19.0%). Incidence of erythema and induration was slightly
lower in participants who received 15 lg ID Intanza vs who
received 7.5 lg ID or 15 lg ID virosomal influenza vaccine. A
higher incidence of erythema after intradermal vaccination in
elderly has been reported in other studies also [31,36,43,44]. As
the vaccine is administered just below the skin surface, local reac-
tions occur earlier and more frequently than after vaccination dee-
per into the muscle [29]. Importantly, the antigens are delivered
into an immune rich environment, which is thought to enhance
the immunogenicity of influenza vaccines. There appeared to be
no correlation between injection volume or injection dose and inci-
dence or severity of local AE’s. It should be noted here that the cur-
rent study being an open-label stud y site investigators and their
clinical collaborators who administered the study vaccines werenot blinded to vaccine treatment arms and when reporting, or
assessing adverse events and their relatedness to vaccination.
Overall, 23 SAEs were reported for 18 study participants among
all vaccine treatment arms. SAEs were reported more commonly in
Inflexal-ID-MJ-7.5vir, Inflexal-ID-MJ-15vir and Fluad-IM-NS-15adj
(6.3–8.2%) compared with other treatment arms (1.6–3.2%). All
SAEs were considered not related to study vaccine and were
resolved by study end except for 1 SAE of polymyalgia rheumatica
in Inflexal-ID-MJ-15vir treatment arm. Three deaths (Fluad-IM-NS-
15adj) reported during the study were considered not related to
study vaccine.
6. Conclusions
This study was intended to compare the ID and high dose
strategies for improving influenza vaccine immunogenicity in the
elderly with an ID device and an adjuvanted vaccine. Safety results
showed that all strategies were generally safe and well-tolerated.
Incidence of solicited local AEs was higher after ID than IM admin-
istration. The ID delivery using microneedles improved immuno-
genicity to standard presentation in at least 2 of 3 strains as
measured by HAI day 22 GMTs. Tripling the dose did not have
any benefit on the vaccine’s immunogenicity over 15 lg IM com-
mercial presentation indicating that in this case a higher HA anti-
gen load in the formulation is not a contributing factor in
improving immune response. Since no direct comparisons between
Fluad-IM-NS-15adj, Intanza-ID-SO-15 and Inflexal-IM-NS-15vir
were conducted, limited conclusions can be made, although
Fluad-IM-NS-15adj and Intanza-ID-SO-15 appeared to have good
immunogenicity across all strains. However, further studies are
required to evaluate direct vaccine efficacy among other effective
parameters.
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